-
Je něco špatně v tomto záznamu ?
Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?
FE. El-Khouly, SEM. Veldhuijzen van Zanten, V. Santa-Maria Lopez, NH. Hendrikse, GJL. Kaspers, G. Loizos, D. Sumerauer, K. Nysom, K. Pruunsild, V. Pentikainen, HK. Thorarinsdottir, G. Rutkauskiene, V. Calvagna, M. Drogosiewicz, M. Dragomir, L....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2009-07-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- biopsie MeSH
- difuzní intrinsický pontinní gliom diagnóza terapie MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- nádory mozkového kmene diagnóza terapie MeSH
- prognóza MeSH
- progrese nemoci MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) is a rare clinically, neuro-radiologically, and molecularly defined malignancy of the brainstem with a median overall survival of approximately 11 months. Our aim is to evaluate the current tendency for its treatment in Europe in order to develop (inter)national consensus guidelines. METHODS: Healthcare professionals specialized in DIPG were asked to fill in an online survey with questions regarding usual treatment strategies at diagnosis and at disease progression in their countries and/or their centers, respectively. RESULTS: Seventy-four healthcare professionals responded to the survey, of which 87.8% were pediatric oncologists. Only 13.5% of the respondents biopsy all of their patients, 41.9% biopsy their patients infrequently. More than half of the respondents (54.1%) treated their patients with radiotherapy only at diagnosis, whereas 44.6% preferred radiotherapy combined with chemotherapy. When the disease progresses, treatment strategies became even more diverse, and the tendency for no treatment increased from 1.4% at diagnosis to 77.0% after second progression. 36.5% of the healthcare professionals treat children younger than 3 years differently than older children at diagnosis. This percentage decreased, when the disease progresses. Most of the participants (51.4%) included less than 25% of their patients in clinical trials. CONCLUSION: This survey demonstrates a large heterogeneity of treatment regimens, especially at disease progression. We emphasize the need for international consensus guidelines for the treatment of DIPG, possible by more collaborative clinical trials.
2nd Department of Pediatrics Semmelweis University Budapest Hungary
Children's Memorial Health Institute Warsaw Poland
CHRU Hautepierre Strasbourg Service de Pédiatrie Onco Hématologie Strasbourg France
Department of Hematology and Oncology Tallinn Children's Hospital Tallinn Estonia
Department of Oncology and Hematology Children's Hospital Zagreb Zagreb Croatia
Department of Pediatric Oncology Hematology Children University Hospital Kosice Slovakia
Department of Pediatric Oncology Our Lady's Children's Hospital Crumlin Dublin Ireland
Department of Pediatrics and Adolescent Medicine Medical University of Vienna Vienna Austria
Department of Radiation Oncology University Medical Center Utrecht Utrecht The Netherlands
Division of Oncology Hematology Department of Pediatrics Haukeland University Hospital Mons Norway
Division of Pediatric Hematology and Oncology University Medical Center Geottingen Göttingen Germany
Great North Children's Hospital Victoria Wing Royal Victoria Infirmary Newcastle upon Tyne UK
Mater Dei Hospital Valletta Malta
Pediatric Hematology Oncology The Children's Hospital Reykjavík Iceland
Pediatric Neurosurgery Charité University Medical Center Berlin Berlin Germany
Pediatric Oncology Hematology Clinic Archbishop Makarios 3 Hospital Nicosia Cyprus
Pediatric Oncology Unit Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
Pediatrics and Adolescent Medicine University Hospital Rigshospitalet Copenhagen Denmark
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20005903
- 003
- CZ-PrNML
- 005
- 20240618123412.0
- 007
- ta
- 008
- 200511s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11060-019-03287-9 $2 doi
- 035 __
- $a (PubMed)31522324
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a El-Khouly, Fatma E $u Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. f.el-khouly@amsterdamumc.nl. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. f.el-khouly@amsterdamumc.nl. Department of Pediatric Oncology/Hematology, Amsterdam UMC, location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. f.el-khouly@amsterdamumc.nl.
- 245 10
- $a Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand? / $c FE. El-Khouly, SEM. Veldhuijzen van Zanten, V. Santa-Maria Lopez, NH. Hendrikse, GJL. Kaspers, G. Loizos, D. Sumerauer, K. Nysom, K. Pruunsild, V. Pentikainen, HK. Thorarinsdottir, G. Rutkauskiene, V. Calvagna, M. Drogosiewicz, M. Dragomir, L. Deak, L. Kitanovski, AO. von Bueren, R. Kebudi, I. Slavc, S. Jacobs, F. Jadrijevic-Cvrlje, N. Entz-Werle, J. Grill, A. Kattamis, P. Hauser, J. Pears, V. Biassoni, M. Massimino, E. Lopez Aguilar, IK. Torsvik, M. Joao Gil-da-Costa, E. Kumirova, O. Cruz-Martinez, S. Holm, S. Bailey, T. Hayden, UW. Thomale, GOR. Janssens, CM. Kramm, DG. van Vuurden,
- 520 9_
- $a INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) is a rare clinically, neuro-radiologically, and molecularly defined malignancy of the brainstem with a median overall survival of approximately 11 months. Our aim is to evaluate the current tendency for its treatment in Europe in order to develop (inter)national consensus guidelines. METHODS: Healthcare professionals specialized in DIPG were asked to fill in an online survey with questions regarding usual treatment strategies at diagnosis and at disease progression in their countries and/or their centers, respectively. RESULTS: Seventy-four healthcare professionals responded to the survey, of which 87.8% were pediatric oncologists. Only 13.5% of the respondents biopsy all of their patients, 41.9% biopsy their patients infrequently. More than half of the respondents (54.1%) treated their patients with radiotherapy only at diagnosis, whereas 44.6% preferred radiotherapy combined with chemotherapy. When the disease progresses, treatment strategies became even more diverse, and the tendency for no treatment increased from 1.4% at diagnosis to 77.0% after second progression. 36.5% of the healthcare professionals treat children younger than 3 years differently than older children at diagnosis. This percentage decreased, when the disease progresses. Most of the participants (51.4%) included less than 25% of their patients in clinical trials. CONCLUSION: This survey demonstrates a large heterogeneity of treatment regimens, especially at disease progression. We emphasize the need for international consensus guidelines for the treatment of DIPG, possible by more collaborative clinical trials.
- 650 _2
- $a biopsie $7 D001706
- 650 _2
- $a nádory mozkového kmene $x diagnóza $x terapie $7 D020295
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a difuzní intrinsický pontinní gliom $x diagnóza $x terapie $7 D000080443
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Veldhuijzen van Zanten, Sophie E M $u Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
- 700 1_
- $a Santa-Maria Lopez, Vicente $u Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, St Joan de Déu Children ́s Hospital, Barcelona, Spain.
- 700 1_
- $a Hendrikse, N Harry $u Department of Clinical Pharmacology & Pharmacy, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Kaspers, Gertjan J L $u Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
- 700 1_
- $a Loizos, G $u Pediatric Oncology-Hematology Clinic, Archbishop Makarios III Hospital, Nicosia, Cyprus.
- 700 1_
- $a Sumerauer, David $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, University Hospital Motol, Charles University, Prague, Czech Republic.
- 700 1_
- $a Nysom, Karsten $u Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark.
- 700 1_
- $a Pruunsild, Kaie $u Department of Hematology and Oncology, Tallinn Children's Hospital, Tallinn, Estonia.
- 700 1_
- $a Pentikainen, Virve $u Division of Hematology-Oncology and Stem Cell Transplantation, Children's Hospital, Helsinki University Hospital, Helsinki, Finland.
- 700 1_
- $a Thorarinsdottir, Halldora K $u Pediatric Hematology-Oncology, The Children's Hospital, Reykjavík, Iceland.
- 700 1_
- $a Rutkauskiene, Giedre $u Department of Pediatric Oncology and Hematology, Hospital of Lithuanian University of Health Sciences Kaunas Clinic, Kaunas, Lithuania.
- 700 1_
- $a Calvagna, Victor $u Mater Dei Hospital, Valletta, Malta.
- 700 1_
- $a Drogosiewicz, Monika $u Children's Memorial Health Institute, Warsaw, Poland.
- 700 1_
- $a Dragomir, Monica $u Department of Pediatric Oncology, Oncology Institute Professor Doctor Alexandru Trestioreanu, Bucharest, Romania.
- 700 1_
- $a Deák, L. $u Department of Pediatric Oncology/Hematology, Children University Hospital, Kosice, Slovakia. $7 xx0318591
- 700 1_
- $a Kitanovski, Lidija $u Division of Hemato-Oncology, Department of Pediatrics, University Medical Center Ljubljana, Ljubljana, Slovenia.
- 700 1_
- $a von Bueren, Andre O $u Pediatric Oncology and Hematology, Department of Pediatrics, University Hospital of Geneva, Geneva, Switzerland.
- 700 1_
- $a Kebudi, Rejin $u Pediatric Hematology-Oncology, Cerrahpasa Medical Faculty & Oncology Institute, Istanbul University, Istanbul, Turkey.
- 700 1_
- $a Slavc, Irene $u Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Jacobs, Sandra $u Universitair Ziekenhuis Leuven, Leuven, Belgium.
- 700 1_
- $a Jadrijevic-Cvrlje, Filip $u Department of Oncology and Hematology, Children's Hospital Zagreb, Zagreb, Croatia.
- 700 1_
- $a Entz-Werle, Natacha $u CHRU Hautepierre Strasbourg, Service de Pédiatrie Onco-Hématologie, Strasbourg, France.
- 700 1_
- $a Grill, Jacques $u Département de Cancérologie de l'enfant et de l'adoloscent, CLCC Institut Gustave Roussy, Villejuif, France.
- 700 1_
- $a Kattamis, Antonis $u First Department of Pediatrics, 'Aghia Sofia' Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- 700 1_
- $a Hauser, Peter $u Second Department of Pediatrics, Semmelweis University, Budapest, Hungary.
- 700 1_
- $a Pears, Jane $u Department of Pediatric Oncology, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland.
- 700 1_
- $a Biassoni, Veronica $u Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- 700 1_
- $a Massimino, Maura $u Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- 700 1_
- $a Lopez Aguilar, Enrique $u Hospital de Pediatría, Centro Médico National Siglo XXI, Instituto Mexicano del Seguro Social, Jefatura de Servicio de Oncologia, Distrito Federal, Mexico.
- 700 1_
- $a Torsvik, Ingrid K $u Division of Oncology/Hematology, Department of Pediatrics, Haukeland University Hospital, Mons, Norway.
- 700 1_
- $a Joao Gil-da-Costa, Maria $u Pediatric Hematology and Oncology Division, University Hospital S. João Alameda Hernani Monteiro, Porto, Portugal.
- 700 1_
- $a Kumirova, Ella $u Department of Neurooncology, Federal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology (FRC-PHOI), Moscow, Russia.
- 700 1_
- $a Cruz-Martinez, Ofelia $u Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, St Joan de Déu Children ́s Hospital, Barcelona, Spain.
- 700 1_
- $a Holm, Stefan $u Department of Pediatric Hematology and Oncology, Department of Woman and Child Health, Karolinska University Hospital, Stockholm, Sweden.
- 700 1_
- $a Bailey, Simon $u Great North Children's Hospital, Victoria Wing, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
- 700 1_
- $a Hayden, Tim $u The DIPG Collaborative, Cincinnati, USA.
- 700 1_
- $a Thomale, Ulrich W $u Pediatric Neurosurgery, Charité University Medical Center Berlin, Berlin, Germany.
- 700 1_
- $a Janssens, Geert O R $u Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
- 700 1_
- $a Kramm, Christof M $u Division of Pediatric Hematology and Oncology, University Medical Center Geottingen, Göttingen, Germany.
- 700 1_
- $a van Vuurden, Dannis G $u Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
- 773 0_
- $w MED00002827 $t Journal of neuro-oncology $x 1573-7373 $g Roč. 145, č. 1 (2019), s. 177-184
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31522324 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20240618123414 $b ABA008
- 999 __
- $a ok $b bmc $g 1524761 $s 1095959
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 145 $c 1 $d 177-184 $e 20190914 $i 1573-7373 $m Journal of neuro-oncology $n J Neurooncol $x MED00002827
- LZP __
- $a Pubmed-20200511
